Warning: mail() has been disabled for security reasons in /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php on line 110

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-content/plugins/bigcontact/BigContact.php on line 43

Warning: Cannot modify header information - headers already sent by (output started at /home/markrref/public_html/usmarketbuzz.com/wp-content/mu-plugins/bps-mu-tools.php:110) in /home/markrref/public_html/usmarketbuzz.com/wp-includes/feed-rss2.php on line 8
Arcadia Biosciences (NASDAQ:RKDA) – US Market Buzz http://www.usmarketbuzz.com Nation and Economy Mon, 20 Jul 2020 16:28:22 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.23 Arcadia Biosciences (NASDAQ:RKDA), Clovis Oncology (NASDAQ:CLVS) Set To Open higher On Monday http://www.usmarketbuzz.com/arcadia-biosciences-nasdaqrkda-clovis-oncology-nasdaqclvs-set-to-open-higher-on-monday-3656 Mon, 04 Mar 2019 13:56:35 +0000 http://www.usmarketbuzz.com/?p=3656 Nano cap Arcadia Biosciences (NASDAQ:RKDA) is up 26% premarket on modestly higher volume in reaction to its Industrial Hemp Pilot Program License in Hawaii, allowing it to cultivate industrial hemp there for agricultural and academic research.

Have you seen the article Forbes wrote about the ASDN Flying Passenger Drone and its technology?

Clovis Oncology (NASDAQ:CLVS) announces that Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Rucaparib is the first PARP inhibitor licensed for an ovarian cancer treatment indication in the EU and is now the first to be available for both treatment and maintenance treatment among eligible patients.

Why Investors Are Calling ASDN the CLVS of the Sky!

Clovis Oncology intends to launch Rubraca in other European countries to follow in 2019 and 2020.

Shares are up 5% premarket.

]]>